Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight

lorundrostatMZE829rilparencelNeutral

AI Analysis

Summary

A market analysis article discusses emerging late-stage therapies for chronic kidney disease including lorundrostat, MZE829, and rilparencel expected to intensify competition through 2036. The article previews a diversified pipeline of treatment modalities addressing the CKD market landscape.

Importance:3/10

Sentiment:

0.20

chronic kidney diseaseemerging therapiesendothelin receptor antagonistsaldosterone synthase inhibitorsAPOL1 inhibitorscell therapymarket analysis

Related Companies

$DHCNL

Read the original article

Published by PR Newswire Clinical Trials on September 24, 2026 2:31 PM

Read Original